Novo Nordisk India partners with Emcure Pharma to distribute and market Poviztra (semaglutide) nationwide, expanding access ...

Emcure Pharma becomes the first Indian company to hold exclusive rights to distribute and commercialise Poviztra, a ...

Novo Nordisk India and Emcure Pharma have partnered to launch Poviztra (semaglutide 2.4 mg), a second brand of Wegovy®, in ...

There’s plenty to like about the lower direct-to-consumer prices the White House negotiated with Eli Lilly and Novo Nordisk. There are also caveats and some unanswered questions.

This collaboration combines Novo Nordisk’s innovation in GLP-1 therapies with Emcure’s marketing and distribution strengths ...

Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide ...

Danish drugmaker Novo Nordisk announced a partnership with Emcure Pharma on Monday to launch its Poviztra, semaglutide injection 2.4 mg, in India. Poviztra is the second brand of its weight loss drug ...

The deal involves Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy. The drugs, known as GLP-1 medications, now cost as much as $1350 a month. Under the ...

After [losing out to Pfizer]( ...

Oral GLP-1 weight loss pills could replace injections by March 2026 at $150 monthly, Medicare chief Dr. Mehmet Oz predicted ...

Hims & Hers Health, Inc. could see more upside in partnerships and international expansion. Click here to read an analysis of ...

New versions of drugs like Wegovy, Ozempic, Mounjaro and Zepbound, including pills, will be easier to take, more effective ...